Tumor burden, chemotherapy, and cell kill in osteosarcoma model

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Background:

• Tumor cell burden, chemotherapy dose, and treatment schedule significantly impact treatment efficacy.
• Accurate dynamic estimation of tumor burden is crucial for understanding drug response.
• Osteosarcoma models in mice provide a valuable platform for investigating these complex relationships.

Purpose of the Study:

• To investigate the relationship between tumor cell burden, chemotherapy dose/schedule, and treatment efficacy.
• To evaluate the effectiveness of Cytoxan in a murine osteosarcoma model at varying tumor burdens.
• To determine optimal treatment strategies for maximizing chemotherapy effectiveness.

Main Methods:

• Utilized a murine osteosarcoma model with a quantifiable marker for dynamic tumor burden estimation.
• Administered Cytoxan (200 mg/kg) at different doses and schedules to animals with varying initial tumor burdens (0.6-10.24% body weight).
• Assessed tumor cell kill and cure rates, with some experiments including immunostimulation.

Main Results:

• Cytoxan achieved >99% tumor cell kill at low burdens (0.6-3% body weight) but <71% kill at higher burdens (5.1-10.24% body weight).
• An aggressive schedule (three doses q12 days) with moderate tumor burden (up to 5%) resulted in significant cell kill (>6 orders of magnitude) and cures, enhanced by immunostimulation.
• A less frequent schedule (two doses q20 days) with higher tumor burden (5-10%) was largely ineffective.

Conclusions:

• Early treatment initiation (low tumor burden) and aggressive chemotherapy schedules are critical for optimal cancer treatment outcomes.
• Treatment delays or prolonged intervals between doses can render effective chemotherapy agents ineffective, independent of biochemical resistance.
• These findings underscore the importance of timely and intensive therapeutic interventions in managing osteosarcoma and potentially other cancers.